Managed Health Care Stocks Technical Review -- WellCare Health Plans, Aetna, Centene, WellPoint, and Molina Healthcare

Editor Note: For more information about this release, please scroll to bottom.

LONDON, July 30, 2014 /PRNewswire/ --

On Tuesday, July 29, 2014, the NASDAQ Composite ended at 4,442.70, down 0.05%, the Dow Jones Industrial Average finished the day 0.42% lower at 16,912.11, and the S&P 500 closed at 1,969.95, down 0.45%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 716.38, down 0.01%, while the index has advanced 1.32% in the last one month. Investor-Edge has initiated coverage on the following equities: WellCare Health Plans Inc. (NYSE: WCG), Aetna Inc. (NYSE: AET), Centene Corporation (NYSE: CNC), WellPoint Inc. (NYSE: WLP), and Molina Healthcare Inc. (NYSE: MOH). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

On Tuesday, shares in WellCare Health Plans Inc. recorded a trading volume of 1.72 million shares, higher than its three months average volume of 0.65 million shares. The stock finished the day at $63.45, up 0.38%, and registered an intraday range of $62.30 and $63.65. Shares of WellCare Health Plans Inc. have declined 15.31% in the last one month and 4.86% in the previous three months. Also, the stock has fallen by 9.90% on YTD basis. Furthermore, the company is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $75.04 is above its 200-day moving average of $69.05. Additionally, shares of the company traded at a PE ratio of 17.39 and have a Relative Strength Index (RSI) of 29.11. Sign up and read the free notes on WCG at:

http://www.Investor-Edge.com/WCG-30Jul2014

Aetna Inc.'s stock declined 3.47%, to close Tuesday's session at $81.88, after oscillating between $81.40 and $84.00. The stock recorded a trading volume of 4.72 million shares, above its three months average volume of 2.16 million shares. Over the last one month and past three months, Aetna Inc.'s shares have gained 0.13% and 16.21%, respectively. Also, from the beginning of 2014, the stock has gone up 19.38%. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $80.62 is above its 200-day moving average of $71.92. Further, Aetna Inc.'s stock traded at a PE ratio of 13.03 and has an RSI of 63.23. The complimentary notes on AET can be downloaded as in PDF format at:

http://www.Investor-Edge.com/AET-30Jul2014

On Tuesday, Centene Corp.'s stock finished the session 1.01% lower at $74.78. A total of 0.78 million shares were traded, which was close to its three months average volume of 0.81 million shares. The stock moved between $74.09 and $75.53 during the session. Over the last one month, Centene Corp.'s shares have declined 0.03%. However, the stock has surged 14.15% over the past three months and 26.85% since the start of this year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $75.32 is greater than its 200-day moving average of $64.78. Centene Corp.'s shares traded at a PE ratio of 23.30 and have an RSI of 47.10. Register for free on Investor-Edge and access the latest research on CNC at:

http://www.Investor-Edge.com/CNC-30Jul2014

Shares in WellPoint Inc. fluctuated between $112.13 and $114.98 before ending Tuesday's session down 2.61%, at $112.55. The company's stock reported a trading volume of 2.97 million shares, above its three months average volume of 1.83 million shares. Further, shares of WellPoint Inc. have rallied 4.65% over the last one month and 17.99% over the past three months. Also, the stock has gained 21.82% on YTD basis. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $109.29 is greater than its 200-day moving average of $96.14. Moreover, shares of WellPoint Inc. traded at a PE ratio of 13.02 and have an RSI of 66.85. The complete research on WLP is available for free at:

http://www.Investor-Edge.com/WLP-30Jul2014

Molina Healthcare Inc.'s stock fell by 1.11%, to close Tuesday's session at $43.69, after vacillating between $43.07 and $44.12. The stock recorded a trading volume of 0.77 million shares, above its three months average volume of 0.63 million shares. Over the last one month, Molina Healthcare Inc.'s shares have fallen by 2.00%. However, over the past three months and from the beginning of 2014, the stock has surged 17.79% and 25.73%, respectively. The company is trading above its 200-day moving average. The stock's 50-day moving average of $44.46 is above its 200-day moving average of $37.87. Further, Molina Healthcare Inc.'s stock traded at a PE ratio of 72.23 and has an RSI of 44.27. Free in depth research on MOH is available at:

http://www.Investor-Edge.com/MOH-30Jul2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


http://Investor-Edge.com

 

SOURCE Investor-Edge

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.